In this work, we find that SOFUSATM delivery of anti-CTLA-4 in an orthotopic 4T1-luc mammary carcinoma murine model results in a greater number of complete responses, significantly reduced tumor growth, and a striking inhibition of distant metastases than when administered systemically. Here, CTLA4 is linked to neoplasm.